Analyzing Health-Related Quality of Life Data to Estimate Parameters for Cost-Effectiveness Models: An Example Using Longitudinal EQ-5D Data from the SHIFT Randomized Controlled Trial

Alison Griffiths, Noman Paracha, Andrew Davies, Neil Branscombe, Martin R Cowie, Mark Sculpher, Alison Griffiths, Noman Paracha, Andrew Davies, Neil Branscombe, Martin R Cowie, Mark Sculpher

Abstract

Introduction: The aim of this article is to discuss methods used to analyze health-related quality of life (HRQoL) data from randomized controlled trials (RCTs) for decision analytic models. The analysis presented in this paper was used to provide HRQoL data for the ivabradine health technology assessment (HTA) submission in chronic heart failure.

Methods: We have used a large, longitudinal EuroQol five-dimension questionnaire (EQ-5D) dataset from the Systolic Heart Failure Treatment with the I f Inhibitor Ivabradine Trial (SHIFT) (clinicaltrials.gov: NCT02441218) to illustrate issues and methods. HRQoL weights (utility values) were estimated from a mixed regression model developed using SHIFT EQ-5D data (n = 5313 patients). The regression model was used to predict HRQoL outcomes according to treatment, patient characteristics, and key clinical outcomes for patients with a heart rate ≥75 bpm.

Results: Ivabradine was associated with an HRQoL weight gain of 0.01. HRQoL weights differed according to New York Heart Association (NYHA) class (NYHA I-IV, no hospitalization: standard care 0.82-0.46; ivabradine 0.84-0.47). A reduction in HRQoL weight was associated with hospitalizations within 30 days of an HRQoL assessment visit, with this reduction varying by NYHA class [-0.07 (NYHA I) to -0.21 (NYHA IV)].

Conclusion: The mixed model explained variation in EQ-5D data according to key clinical outcomes and patient characteristics, providing essential information for long-term predictions of patient HRQoL in the cost-effectiveness model. This model was also used to estimate the loss in HRQoL associated with hospitalizations. In SHIFT many hospitalizations did not occur close to EQ-5D visits; hence, any temporary changes in HRQoL associated with such events would not be captured fully in observed RCT evidence, but could be predicted in our cost-effectiveness analysis using the mixed model. Given the large reduction in hospitalizations associated with ivabradine this was an important feature of the analysis.

Funding: The Servier Research Group.

Keywords: Application areas; Cardiovascular; Cost-effectiveness; Economics; Heart failure; Ivabradine; Quality of life.

Figures

Fig. 1
Fig. 1
SHIFT EQ-5D HRQoL data. EQ-5D EuroQol five-dimension questionnaire. Normal probability plot depicts expected EQ-5D values based on the standard normal distribution versus observed EQ-5D values. Histogram depicts observed frequency for each EQ-5D score (all observations) with kernel density smoother overlaid

References

    1. NICE. Guide to the methods of technology appraisal. London: NICE; 2013.
    1. EuroQol Group. EQ-5D. . Accessed Feb 2010.
    1. Torrance GW. HRQoL weights approach to measuring health-related quality of life. J Chronic Dis. 1987;40(6):593–603. doi: 10.1016/0021-9681(87)90019-1.
    1. Griffiths A, Paracha N, Davies A, Branscombe N, Cowie MR, Sculpher M. The cost effectiveness of ivabradine in the treatment of chronic heart failure from the U.K. National Health Service perspective. Heart (British Cardiac Society). 2014;100(13):1031–6.
    1. NICE. Technology Appraisal 267: ivabradine for the treatment of chronic heart failure. London: NICE; 2013.
    1. BHF. British Heart Foundation: morbidity 2010. . Accessed Feb 2010.
    1. BHF. British Heart Foundation. Heart health conditions: heart failure 2013. . Accessed Feb 2010.
    1. Swedberg K, Komajda M, Bohm M, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet (London, England). 2010;376(9744):875–85.
    1. Ekman I, Chassany O, Komajda M, et al. Heart rate reduction with ivabradine and health related quality of life in patients with chronic heart failure: results from the SHIFT study. Eur Heart J. 2011;32(19):2395–2404. doi: 10.1093/eurheartj/ehr343.
    1. Kind P, Hardman G, Macran S. UK population norms for EQ-5D. Discussion paper 172. York: University of York, Centre for Health Economics; 1999.
    1. Briggs AH, Parfrey PS, Khan N, et al. Analyzing health-related quality of life in the EVOLVE trial: the joint impact of treatment and clinical events. Med Decis Making. 2016;36:965–72.
    1. Goldstein H. Multilevel statistical models. London: Arnold; 2003.
    1. Hubbard AE, Ahern J, Fleischer NL, et al. To GEE or not to GEE: comparing population average and mixed models for estimating the associations between neighborhood risk factors and health. Epidemiology (Cambridge, Mass). 2010;21(4):467–74.
    1. Rabe-Hesketh S, Skrondal A. Multilevel and longitudinal modelling using STATA volumes 1 and 2. College Station: Stata Press; 2012.
    1. Swedberg K, Komajda M, Bohm M, et al. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study. J Am Coll Cardiol. 2012;59(22):1938–1945. doi: 10.1016/j.jacc.2012.01.020.
    1. StataCorp. Stata statistical software: release 11. College Station, TX: StataCorp LP; 2009.
    1. Gohler A, Geisler BP, Manne JM, et al. HRQoL weights estimates for decision-analytic modeling in chronic heart failure–health states based on New York Heart Association classes and number of rehospitalizations. Value Health. 2009;12(1):185–187. doi: 10.1111/j.1524-4733.2008.00425.x.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj